lodoxamide tromethamine
Trade name: alomide
Small moleculeapprovedOrphan Drug FDA
Approved
Sep 23, 1993
Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer. In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Molecular identity unknownUnknown
Molecular identity unknown unknown
Approval history
- approvedSep 23, 1993
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO- Mol. weight
- 432.77 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLodoxamide ↗
- ChEMBLCHEMBL1201175 ↗
Also known as
- 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxoacetic acid), compd. with 2-amino-2- (hydroxymethyl)-1,3-propanediol (1:2)
- alomide
- alomide
- alomide
- alomide
- alomide
- alomide allergy
- lodoxamide trometamol
- lodoxamide trometamol
- lodoxamide trometamol
- lodoxamide tromethamine
- lodoxamide tromethamine
- lodoxamide tromethamine
- lodoxamide tromethamine
- lodoxamide tromethamine
- lodoxamide tromethamine
- u 42585 e
- u-42585e
- u-42585e
- u-42,585e
- u-42,585e